Nanomedicine: Nanotechnology, Biology and Medicine
Volume 8, Issue 2 , Pages 167-175, February 2012

Linear PEI nanoparticles: efficient pDNA/siRNA carriers in vitro and in vivo

  • Ritu Goyal, MPhil

      Affiliations

    • CSIR-Institute of Genomics and Integrative Biology, Delhi University, Delhi, India
  • ,
  • Sushil K. Tripathi, MSc

      Affiliations

    • CSIR-Institute of Genomics and Integrative Biology, Delhi University, Delhi, India
  • ,
  • Shilpa Tyagi, MSc

      Affiliations

    • CSIR-Indian Institute of Toxicology Research, Lucknow, India
  • ,
  • Anurag Sharma, MSc

      Affiliations

    • CSIR-Indian Institute of Toxicology Research, Lucknow, India
  • ,
  • K. Ravi Ram, PhD

      Affiliations

    • CSIR-Indian Institute of Toxicology Research, Lucknow, India
  • ,
  • Debapratim K. Chowdhuri, PhD

      Affiliations

    • CSIR-Indian Institute of Toxicology Research, Lucknow, India
  • ,
  • Yogeshwar Shukla, PhD

      Affiliations

    • CSIR-Indian Institute of Toxicology Research, Lucknow, India
  • ,
  • P. Kumar, PhD

      Affiliations

    • CSIR-Institute of Genomics and Integrative Biology, Delhi University, Delhi, India
  • ,
  • Kailash C. Gupta, PhD

      Affiliations

    • CSIR-Institute of Genomics and Integrative Biology, Delhi University, Delhi, India
    • CSIR-Indian Institute of Toxicology Research, Lucknow, India
    • Corresponding Author InformationCorresponding author: Indian Institute of Toxicology Research, Mahatma Gandhi Marg, Lucknow-226001, India.

Received 16 October 2010; accepted 2 June 2011. published online 16 June 2011.

Abstract 

Linear polyethylenimine (lPEI, 25 kDa) nanoparticles' (LPN) series was synthesized by varying percentage of cross-linking with 1,4-butanediol diglycidyl ether (BDE) and their size, surface charge, morphology, pDNA protection/release, cytotoxicity and transfection efficiency were evaluated. Synthesized nanoparticles (NPs) were spherical in shape (size: ∼109 – 235 nm; zeta potential: +38 to +16 mV). These NPs showed increased buffering capacity with increasing percent cross-linking and also exhibited excellent transfection efficiency (i.e., ∼1.3 – 14.7 folds in case of LPN-5) in comparison with lPEI and the commercial transfection agents used in this study. LPN-5 based GFP-specific siRNA delivery resulted in ∼86% suppression of targeted gene expression. These particles were relatively nontoxic in vitro (in cell lines) and in vivo (in Drosophila). In vivo gene expression studies using LPN-5 in Balb/c mice through intravenous injection showed maximum expression of the reporter gene in the spleen. These results together demonstrate the potential of these particles as efficient transfection reagents.

From the Clinical Editor

The authors demonstrate a novel method of synthesizing linear PEI nanoparticles to utilize these as transfection agents.

Graphical Abstract 

A series of lPEI nanoparticles (LPNs) has been synthesized keeping intact the overall amines and cell viability characteristics of lPEI using BDE as a crosslinker. These LPNs exhibited significantly improved transfection efficiency with relatively negligible cytotoxicity compared to bPEI, lPEI and other commercially available transfection reagents both in vitro and in vivo.

Key words: Linear polyethylenimine, 1,4-butanediol diglycidyl ether, In vivo gene expression, Drosophila, In vivo cytotoxicity

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 No conflict of interest was reported by the authors of this article.

 Financial support from the CSIR (NWP-035) and UGC-SRF (10-2(05)2006(i)-E.U.II) to RG is gratefully acknowledged.

PII: S1549-9634(11)00254-1

doi:10.1016/j.nano.2011.06.001

Nanomedicine: Nanotechnology, Biology and Medicine
Volume 8, Issue 2 , Pages 167-175, February 2012